Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer.

Journal of molecular endocrinology - 1 Nov 2017

Tesselaar Marika H, Smit Johannes W, Nagarajah James, Netea-Maier Romana T, Plantinga Theo S

Abstract excerpt

While in most patients with non-medullary thyroid cancer (TC), disease remission is achieved by thyroidectomy and ablation of tumor remnants by radioactive iodide (RAI), a substantial subgroup of patients with metastatic disease present tumor lesions that have acquired RAI resistance as a result of dedifferentiation. Although oncogenic mutations in BRAF, TERT promoter and TP53 are associated with an increased...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Combined Modality Therapy
Share to Epithelial-Mesenchymal Transition

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunomodulation

Share to Iodine Radioisotopes

Share to Metabolic Networks and Pathways

Share to Neoplastic Stem Cells

Share to Radiation Tolerance

Share to Retreatment

Source

Identifiers

PMID: 28931558
DOI: 10.1530/JME-17-0134

Genes

BRAF
TERT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer.PMID 28931558Read ↗

TERT mutations and aggressive histopathologic characteristics of radioiodine-refractory papillary thyroid cancerSemantic proximity Read ↗

Molecular and Proteomic Profiles of Radioiodine Refractory Papillary Thyroid CancerSemantic proximity Read ↗

IGF2 is a Potential Factor in RAI-refractory Non-medullary Thyroid CancerSemantic proximity Read ↗

Update on Fundamental Mechanisms of Thyroid Cancer.Semantic proximity Read ↗

Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.Semantic proximity Read ↗

Update on the molecular diagnosis and targeted therapy of thyroid cancer.Semantic proximity Read ↗

Novel targeted therapies and immunotherapy for advanced thyroid cancers.Semantic proximity Read ↗

Clinical and Translational Challenges in Thyroid Cancer.Semantic proximity Read ↗

MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectivesSemantic proximity Read ↗

[What's new in follicular thyroid cancer management in 2014?].Semantic proximity Read ↗

The Role of the Kinase Inhibitors in Thyroid CancersSemantic proximity Read ↗

Review of Genomic Drivers of Thyroid Cancer and Their Clinical Implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.